Pelthos Therapeutics (PTHS) reported third-quarter 2026 total revenue of $15.4 million and a net loss of $7.9 million, or $2.04 per basic and diluted share. Zelsuvmi net product revenue rose 114% year over year to $15.2 million.
The company said it had 127 million commercially covered lives for Zelsuvmi as of the third quarter and announced an agreement in October to combine with Castle Creek Biosciences.
- Zelsuvmi units dispensed totaled 12,384, up 4% sequentially and 365% year over year.
- Cash and cash equivalents were $17.7 million as of September 30, 2026.
- Pelthos borrowed an additional $10.0 million under its Horizon Technology Finance facility on October 30, bringing outstanding borrowings to $40.0 million.
- The Castle Creek transaction is expected to close by the end of the first quarter of 2027, subject to customary conditions.
EARLY ACCESS
Receive CHRO Data Alerts
Real-time alerts on filings, insider trades, and market signals — before everyone else.
Get Alerts →
